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The purpose of this study was to describe current prenatal and pediatric genetic 
counseling practice following a non-invasive prenatal testing (NIPT) result positive for a sex 
chromosome abnormality (SCA).  The positive predictive value for SCA with NIPT is lower 
than seen for Trisomy 21 due to natural loss of the X chromosome from maternal cells 
during aging, confined placental mosaicism, and undiagnosed maternal sex chromosome 
abnormality.  Except for 45,X, individuals with SCA usually have no ultrasound or postnatal 
findings. This makes follow-up for unresolved positive NIPT necessary; however, there are 
currently no clinical guidelines.  This study used a prospective anonymous questionnaire to 
survey 176 prenatal and pediatric genetic counselors.  Greater than 70% of pediatric 
respondents and >80% of prenatal respondents were somewhat or extremely comfortable 
counseling patients about SCAs.  However, prenatal respondents in the field for <5 years 
were significantly less comfortable counseling about every condition except 45,X (p<0.02).  
A majority of prenatal respondents always offered diagnostic testing (>88%) and anatomy 
ultrasound (~90%), but the percent consistently offering maternal karyotype (22-52%) and 
postnatal evaluation (28-87%) varied.  Maternal karyotype was offered more often when 
NIPT was positive for 45,X or 47,XXX and patients had normal diagnostic testing (p<0.023) 
or declined testing (p<0.019).  Offer of postnatal evaluation was more likely when 
diagnostic testing was declined (p<0.01).  A majority of pediatric providers always offered 
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the child a karyotype postnatally (>72%) but the percent offering maternal karyotype (6-
46%) varied widely.  With the current inconsistencies, many newborns with undiagnosed 
SCAs who could benefit from growth hormone therapy, early intervention, and/or targeted 
surveillance may be missed.  There is a need for professional guidelines to help improve 
clinical care for patients with NIPT results positive for SCAs.   
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INTRODUCTION 
Research has been ongoing for decades to create a highly sensitive non-invasive 
screening method for fetal chromosome abnormalities during pregnancy.  Following the 
identification of fetal leukocytes in the maternal blood stream during pregnancy in the late 
1960s, there was hope that these cells could be used for prenatal screening, and 
potentially diagnosis, of chromosome abnormalities (1).  However, further research 
discovered that these fetal cells persist in the maternal blood stream for years following the 
birth of a baby.  This finding decreased the clinical utility of fetal leukocytes since it is 
technically difficult to determine which cells came from which pregnancy in a multiparous 
woman (2).  Therefore, scientists continued to look for other ways to use the maternal 
bloodstream to learn about fetal genetic characteristics.          
In the late 1990s, it was determined that cell-free DNA of placental origin is present 
in the maternal bloodstream during pregnancy at an average concentration of 10% (3, 4).  
This discovery of cell free DNA (cfDNA) led to a flurry of experimentation to determine 
whether this could be used to provide meaningful information about genetic characteristics 
of a pregnancy in a non-invasive manner.   
It has since been determined that cfDNA can be reliably used to screen for fetal 
aneuploidy using several techniques (5).  Testing using cfDNA is referred to by several 
names including cell free DNA, non-invasive prenatal screening (NIPS), and non-invasive 
prenatal testing (NIPT).  CfDNA is largely placental in origin, and therefore may not be 
representative of the complete genetic composition of the fetus in some cases (6).  For this 
reason, NIPT is still considered a screening test and diagnostic testing is recommended 
following a positive result.  When laboratories first introduced NIPT for high risk women in 
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2011, the test only screened for trisomy 21.  Screening for trisomies 18, 13 and the 
presence or absence of Y chromosome was introduced in 2012.  
While labs offering NIPT often quote their own statistics for sensitivity and 
specificity, a 2015 meta-analysis by Gil et al. determined a detection rate of 99.2% for 
Trisomy 21, 96.3% for Trisomy 18, and 91% for Trisomy 13.  The false positive rates from 
this analysis were <0.1%, 0.13%, and 0.13% respectively (7).  Therefore, NIPT has a 
higher detection rate and lower false positive rate compared with other screening tests for 
aneuploidy, specifically first trimester screening and quadruple marker screening (8).  This 
makes it an alluring test for soon to be parents who desire the most accurate information 
without the risk of miscarriage associated with invasive testing.  
Since 2013, NIPT has included sex chromosome abnormalities as well as the three 
common autosomal aneuploidies (9).  Sex chromosome abnormalities (SCA) are genetic 
conditions in which an individual has an abnormal number of sex chromosomes.  As a 
group, SCAs are the most common chromosome abnormalities present at birth, occurring 
in every 1 in 300-400 live births (10).  The most common are 45,X (Turner Syndrome) and 
other karyotypes, and 47,XXY (Klinefelter Syndrome).  Other abnormal sex chromosome 
complements include 47,XXX and 47,XYY.  The risk of having an affected child with 
47,XXX and 47,XXY increases as maternal age increases like the maternal age effect seen 
for the common autosomal aneuploidies.  However, 45,X and 47,XYY are thought to occur 
with a similar frequency throughout the population.  While not associated with increased 
paternal age, 100% of 47,XYY cases and about 50-66% of 45,X cases derive from paternal 
origin (11).   
Screening for SCAs by NIPT is challenging for several reasons, including fetal and 
maternal factors.  Approximately 1-2% of pregnancies have confined placental mosaicism, 
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when a chromosome complement in all or part of the placenta is discordant from that of the 
fetus.  Therefore, when evaluating cfDNA from the placenta, there is a risk to obtain a false 
positive or false negative result due to confined placental mosaicism (12).  A 2015 study by 
Malvestiti et al. found that of pregnancies with an abnormal CVS for a SCA, 33% had fetal 
involvement on amniocentesis while 67% were not confirmed in amniocytes (13).  
Discrepancies have been found to be true for other chromosome conditions as well. 
Additional challenges unique to SCAs include maternal factors, such as the loss of 
an X chromosome from maternal cells as a natural part of aging, and maternal SCA 
mosaicism or full maternal SCA.  Since both maternal and placental DNA are examined by 
NIPT, any differences in maternal DNA could lead to an abnormal result.  Maternal cells 
have been shown to naturally lose an X chromosome as a woman ages, which could skew 
the amount of X chromosome available for quantification (14).  A 2007 study looking at the 
frequency of X chromosome loss in women from birth to age 80 found a frequency of X 
chromosome loss of approximately 1% for women under age 30, 2% for women at age 40, 
and 3% for women at the age of 50 (15).  In addition, there is evidence to support that 
most, if not all, women with 45,X have some level of mosaicism (16).  About 2% of women 
with 45,X spontaneously achieve pregnancy and may not know that they have a 45,X cell 
line.  There are also women who have 45,X, 47,XXX or a double aneuploidy (ex. 
45,X/47,XXX) but have never had genetic testing and are therefore not aware that they 
have an extra or missing chromosome.  In 2013, Wang et al. found that 8.6% of 
pregnancies in their sample with NIPT positive for a SCA were due to maternal 
abnormalities in X chromosome number.  Research into these phenomena illustrates how 
maternal and placental abnormalities can confound NIPT results.  
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These biologic phenomena increase the false positive rate of the test thereby 
decreasing the positive predictive value (PPV) of NIPT for SCAs.  The sex chromosome 
abnormalities are quoted to have a PPV of approximately 20-50%, making it difficult to 
counsel patients with a positive result, many of whom may think that the chances of an 
affected pregnancy are much higher based on detection rate alone (17).  As reported by Gil 
et al. in their 2015 meta-analysis, 45,X has a detection rate of 90.3% and a false positive 
rate of 0.23%, while all other sex chromosome aneuploidies had a combined detection rate 
of 93% and a false positive rate of 0.14%.  It is important to note that in the study the 
confidence intervals for SCA conditions had a wider range than the autosomal trisomies 
(7).     
Following positive NIPT for one of the autosomal aneuploidies, a high-resolution 
ultrasound is often used to adjust the likelihood of having an affected pregnancy.  This is 
more complicated with SCAs.  In 45,X, ultrasound findings may include increased nuchal 
translucency, cystic hygroma, hydrops, heart defects, and kidney defects.  It has been 
reported that 68% of fetuses with 45,X have some type of sonographic finding (18).  While 
these ultrasound findings increase the likelihood of the fetus having 45,X, the exact 
diagnosis is based on karyotype results and phenotype and can only be appropriately 
ascertained postnatally with a physical examination and pelvic ultrasound making it 
necessary for patients to have appropriate follow up.  Other sex chromosome abnormalities 
often have no ultrasound findings with which to guide the counseling and testing path, but a 
karyotype is sufficient to diagnose or rule out the condition.  If a patient has normal 
diagnostic testing or declines diagnostic testing, there is ambiguity regarding the reason for 
a positive NIPT result and the healthcare professional is left in a dilemma as to next steps.  
Based on the known reasons for a false positive result, further investigation into the 
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positive result might include offering maternal karyotype or a genetics evaluation after birth 
with a karyotype on the neonate.     
Difficulty in knowing how to counsel patients about a positive NIPT for SCAs is a 
potential problem currently facing the genetic counseling profession.  A 2015 study by 
Geeter examined genetic counselors’ views on the issues surrounding the use of NIPT to 
screen for SCAs.  There was consensus among genetic counselors concerning what was 
necessary to discuss with patients both in pre- and post-test counseling, including the 
phenotypic variability seen in these conditions, why a false positive result might occur, and 
the PPV (19).  However, there is a lack of information on what genetic counselors offer 
patients following a positive NIPT for a SCA, in the absence of diagnostic confirmation, to 
help determine the likelihood of a true positive or undiscovered mosaicism in a child or 
woman.   
Individuals with SCAs benefit from diagnosis at a young age so that appropriate 
management via early intervention, hormone treatment, and specialized surveillance can 
take place leading to better outcomes.  Even though not ideal to be uncovered in 
adulthood, discovering maternal SCA can have important implications for future health, as 
women with 45,X have increased lifelong risks for hearing loss, aortic root dilation, and 
fractures, and women with 47,XXX may be at risk of primary ovarian insufficiency (20, 21).  
As well, individuals with 45,X and 47,XXY are at an increased risk for a pregnancy with a 
SCA if they are able to achieve pregnancy (22).  Having a diagnosis is therefore important 
for future management and treatment in patients.    
As the use of NIPT continues among pregnant women, receiving NIPT results 
positive for SCAs and dealing with unresolved prenatal testing will continue to be a daily 
part of prenatal genetic counseling practice, and the number of referrals to medical 
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genetics postnatally for these cases will increase.  Therefore, this study was designed to 
evaluate current genetic counseling practices in regards to follow up testing and 
management for patients with positive NIPT results for a SCA.    
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METHODS 
Participants 
 Eligible study participants included currently practicing genetic counselors in 
prenatal and pediatric genetics who see patients as part or all of their current position.  
Genetic counselors who do not see patients in prenatal or pediatrics, or who work in a non-
clinical setting, were excluded from the study.  Genetic counselors were recruited using the 
National Society of Genetic Counselors (NSGC) student research eblast which targeted the 
overall membership, as well as the Pediatric and Clinical Genetics Special Interest Group 
and Prenatal Special Interest Group.  Overall, the survey was sent to 3,535 individuals 
through the full membership eblast.  Using the number of NSGC members listing pediatric 
or prenatal as their specialty on their NSGC profile, it is estimated that the survey was sent 
to approximately 1,290 prenatal counselors and 749 pediatric counselors.  Overall, there 
were 176 eligible respondents to the survey giving an estimated response rate of 8.6%.  Of 
the total respondents, 122 were by counselors who exclusively see prenatal patients, 28 
were by counselors who exclusively see pediatric patients, and 13 were by counselors who 
indicated they see both prenatal and pediatric patients. 
Instrumentation 
 The study used a prospective anonymous questionnaire that was created by the 
authors using the survey software Qualtrics (Appendix A).  The survey was made up of 
three sections.  The first section included nine questions about demographic information 
such as number of years practiced, job setting, specialty, and state of practice.  All 
participants completed the demographic section and were then directed to the appropriate 
section based on current specialty.  Section two was for pediatric genetic counselors and 
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was made up of 21 questions. Information gathered included number and type of SCA 
cases seen, comfort level with counseling patients about various SCA indications, and four 
clinic scenarios which evaluated current practice for different SCA NIPT results.  The third 
section was for prenatal genetic counselors and was made up of 34 questions.  Information 
gathered was similar to section two, including number and type of SCA cases seen, 
comfort level in counseling patients about SCA conditions, and four scenarios to evaluate 
current practice for different SCA results.  Respondents were not required to answer all 
questions.  For sections two and three, the four scenarios asked about the same SCA 
conditions in context of the practice area.  Scenarios 1 and 2 asked about NIPT positive for 
45,X with or without ultrasound or physical findings, scenario 3 asked about NIPT positive 
for 47,XXX, and scenario 4 asked about NIPT positive for 47,XYY.  The 13 respondents 
who indicated working in both the pediatric and prenatal fields were presented with 
sections two (pediatric) and three (prenatal) in a randomized fashion.  Six respondents 
received the pediatric section first and seven received the prenatal section first.  
Participants who completed the survey were given the opportunity to provide their email 
address in a separate unlinked window for consideration in the drawing of two $50 Visa gift 
cards.    
Procedures 
 A proposal of the study was approved by the University of Texas Institutional 
Review Board, which is governed by the Committee for the Protection of Human Subjects 
(HSC # 17-0586).   Following IRB approval, an email containing a description of the study, 
invitation to participate, and link to the survey was sent to all eligible participants through 
the NSGC student research eblast.  The online survey tool Qualtrics was used to 
administer the survey via email and collect data.  The survey was sent to the full NSGC 
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membership as well as the Pediatric and Clinical Genetics Special Interest Group and 
Prenatal Special Interest Group in September and October 2017.   
Anonymous survey responses were gathered in password protected Qualtrics 
software and stored on a secure UT Health computer. Only the principal investigator and 
co-investigator had access to the stored data.  Data did not contain any PHI or other 
personally identifying information.  However, participants who completed the full survey 
had the option of submitting an email address through a separate unlinked window to be 
considered for the drawing of one of two $50 Visa gift cards.  In total, 114 respondents 
provided an email address for the gift card drawing.  Email addresses were used only for 
the incentive and will not be used for future contact.     
Data Analysis 
 Data was described using frequencies and percentages.  Following initial data 
collection, scenario-based questions were grouped for comparison.  Answers to the 
scenario questions ranged from 0-100%.  The raw data was recategorized into the 
following five categories: never (0%), rarely (1-33%), sometimes (34-66%), often (67-99%), 
and always (100%).  This recategorization was done to aid in meaningful data 
interpretation due to the non-normal distribution of the data.  Differences in responses by 
individuals between scenarios was analyzed using the Wilcoxon Signed-Rank Test.  
Differences in responses for each scenario between respondents in the field for <5 years 
and those in the field for ≥5 years was analyzed using a Mann-Whitney test.  Data was 
analyzed by Stata (v. 14.1, College Station, TX) using a level of significance at p<0.05.               
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RESULTS 
Demographics 
In total, 3,535 genetic counselors were invited to take the survey of which 
approximately 2,039 were eligible to participate.  There were 204 responses.  Of those 
responses, 14 were excluded because they were not clinical genetic counselors and 14 
more were excluded because they did not see prenatal or pediatric patients.  Thus, 176 
respondents were eligible to participate in the survey.  Of the 176 eligible respondents, 135 
indicated that they exclusively see prenatal patients, 28 indicated that they exclusively see 
pediatric patients, and 13 indicated that they see both prenatal and pediatric patients.  Most 
prenatal counselors worked in a university medical center (42%), had worked in the field for 
more than 5 years (53%), and saw 11-20 patients per week (56%) (Table 1).  Most 
pediatric counselors worked in a university medical center (51%), had worked in the field 
for less than 5 years (88%), and saw 1-10 patients per week (74%) (Table 1).  Years in a 
prenatal or pediatric specialty were classified based on whether a respondent had started 
practicing prior to the introduction of NIPT (≥5 years) or since its introduction (<5 years).  
Among prenatal counselors, 47% had been in the field for less than 5 years, and 88% of 
pediatric counselors had been in the field for less than 5 years.  Of the 13 respondents who 
saw both prenatal and pediatric patients, 58% had been seeing prenatal patients for less 
than 5 years and 50% had been seeing pediatric patients for less than 5 years (Table 1).  
There were no significant differences between respondents seeing both prenatal and 
pediatric patients and those seeing patients in only one specialty.  Survey respondents 
were from 41 states. 
 
11 
 
Table 1: Participant Demographics      
Variable    n % 
Work Setting (n=176)     
  University medical center 79 44.9 
  
Private hospital/medical 
facility 44 25.0 
  
Public hospital/medical 
facility 39 22.2 
  Physician's private practice 14 8.0 
Prenatal Respondents (n=148)     
Years as a prenatal genetic counselor only (n=126)*    
  <5 59 46.8 
  >=5 67 53.2 
Years as a prenatal genetic counselor for respondents doing both specialties 
(n=12)* 
   
  <5 7 58.3 
  >=5 5 41.7 
Patients seen per week (n=146)*    
  1-10 36 24.6 
  11-20 82 56.2 
  21-30 22 15.1 
  31+ 6 4.1 
Clinic services offered      
  CVS 123 88.5 
  Amniocentesis 137 99.3 
  NIPT 141 98.6 
Pediatric Respondents (n=41)     
Years as a pediatric genetic counselor only (n=25)*    
  <5 22 88.0 
  >=5 3 12.0 
Years as a pediatric genetic counselor for respondents doing both specialties 
(n=12)* 
   
  <5 6 50.0 
  >=5 6 50.0 
Patients seen per week (n=39)*    
  1-10 29 74.4 
  11-20 10 25.6 
* No response: years as a prenatal GC only (n=9), years as a prenatal genetic counselor for 
respondents doing both specialties (n=1), prenatal patients seen per week (n=2), years as a 
pediatric genetic counselor only (n=3), years as a pediatric counselor for respondents doing 
both specialties (n=1), pediatric patients seen per week (n=2) 
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Table 2: Sex Chromosome Abnormality Cases Seen 
Prenatal  n % 
SCA case seen? (n=136) yes 128 94.1 
 no 8 5.9 
SCA cases seen  45,X 115 89.8 
 47,XXY 78 60.9 
 47,XXX 67 52.3 
 47,XYY 40 31.3 
 Other 10 7.8 
Pediatric  n % 
SCA case seen? (n=40) yes 33 82.5 
 no 7 17.5 
SCA cases seen 45,X 24 72.7 
 47,XXY 21 63.6 
 47,XXX 15 45.5 
 47,XYY 8 24.2 
 Other 2 6.1 
 
Prenatal section         
A total of 148 individuals were eligible to take the prenatal portion of the survey.  Of 
these respondents, 94.1% indicated they had seen at least one patient with NIPT positive 
for a SCA (Table 2).  When asked about type of SCA cases seen in the last year, 45,X was 
the most common answer (89.8%) followed by 47,XXY (60.9%), 47,XXX (52.3%), 47,XYY 
(31.3%), and “other” SCA results (7.8%), including suspected maternal 45,X mosaicism, 
non-reportable X, XXY, and reported sex discrepant with ultrasound (Table 2).  When 
asked what their clinic offers to patients, the majority of respondents indicated their clinic 
offers CVS, amniocentesis, and NIPT to patients (Table 1).  NIPT that includes analysis of 
chromosomes 13, 18, 21, and SCAs was the most commonly used NIPT among 
respondents, with 22% indicating they offer this option all the time.  When seeing a patient 
with a positive NIPT, 83% of respondents said they always discuss the positive predictive 
value (PPV).  When asked about comfort level in counseling prenatal patients for a positive 
NIPT for a SCA, greater than 90% of respondents indicated they were somewhat or 
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extremely comfortable counseling patients about the more common SCAs (45,X, 47,XXX, 
47,XXY, and 47,XYY).  However, only 80% of respondents indicated being comfortable 
when counseling patients for “other” SCA results (Figure 1; Table 3).  While overall 
respondents self-reported being comfortable counseling about these indications, 
respondents in the field for less than 5 years were significantly less comfortable than those 
in the field for 5 or more years counseling about 47,XXY (p=0.02), 47,XXX (p=0.003), 
47,XYY (p=0.001), and “other” SCA results (p=0.0001).  
 
 
In the scenarios, when asked what they would offer at an initial appointment for a 
positive NIPT for 45,X with or without ultrasound findings (scenarios 1 and 2), 47,XXX 
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Figure 1: Prenatal Genetic Counselor Comfort Level About 
Discussing Various SCA Conditions With Patients
45,X 47,XXY 47,XXX 47,XYY Other
Table 3: Prenatal Respondents Self-Reported Comfort Level Counseling About SCA Conditions
Prenatal Comfort 45, X 47, XXY 47, XXX 47, XYY Other
Extremely Uncomfortable 2.6% (n=3) 2.6% (n=3) 2.6% (n=3) 1.8% (n=2) 1.8% (n=2)
Somewhat Uncomfortable 1.8% (n=2) 0.9% (n-1) 0.9% (n=1) 1.8% (n=2) 3.5% (n=4)
Neither Comfortable nor 
Uncomfortable
0% (n=0) 2.6% (n=3) 3.5% (n=4) 4.4% (n=5) 14.2% (n=16)
Somewhat Comfortable 19.3% (n=22) 29.8% (n=34) 30.7% (n=35) 38.1% (n=43) 41.6% (n=47)
Extremely Comfortable 76.3% (n=87) 64.0% (n=73) 62.3% (n=71) 54.0% (n=61) 38.9% (n=44)
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(scenario 3), or 47,XYY (scenario 4) the vast majority of prenatal genetic counselors 
always offered diagnostic testing (either CVS [>88%] and or amniocentesis [>90%]), and 
prenatal ultrasound (>90%) to patients (Table 4).  Other options including chromosome 
microarray (CMA), single gene testing, maternal testing through either karyotype or X,Y 
FISH, and postnatal evaluation, exhibited variability in the frequency with which the option 
was being offered between and within scenarios.  These patterns held true across 
scenarios with a few notable exceptions.  With NIPT positive for 45,X and a cystic hygroma 
on ultrasound (scenario 2), respondents were significantly more likely to offer their patient a 
CMA and or single gene testing if the patient had had a normal karyotype through CVS or 
amniocentesis (p<0.01).  As well, respondents were significantly more likely to offer a CMA 
at the initial appointment of a patient with NIPT positive for 45,X and ultrasound findings 
(scenario 2; p<0.01) and/or if a patient had NIPT positive for 47,XXX (Scenario 3; p=0.016) 
than they were for a patient with NIPT positive for 45,X and no ultrasound findings 
(scenario 1).  Across scenarios, respondents were significantly less likely to offer a 
postnatal evaluation to a patient who had a normal karyotype with diagnostic testing 
compared to a patient at the initial appointment (p<0.01).  With the exception of a patient 
with NIPT positive for 47,XYY (scenario 4), respondents were significantly more likely to 
offer a postnatal evaluation to a patient who declined diagnostic testing during pregnancy 
than to a patient who had a normal karyotype during the pregnancy (p<0.01).  Looking at 
the frequency with which respondents offered maternal karyotype, respondents were 
significantly more likely to offer a maternal karyotype to patients with NIPT positive for 45,X 
with or without ultrasound findings (scenarios 1 and 2) and to patients with NIPT positive 
for 47,XXX (scenario 3) following a normal karyotype result (p=0.023, p=0.022, and p<0.01 
respectively) or if the patient declined diagnostic testing (p=0.014, p<0.01, and p=0.019 
respectively) than they were to offer it at the initial appointment.  For maternal X,Y FISH, 
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respondents were significantly more like to offer it to a patient with NIPT positive for 45,X 
with or without ultrasound findings (scenarios 1 and 2) following normal karyotype on 
diagnostic testing than at the initial appointment (p=0.028, and p=0.014).  However, 
respondents only offered maternal X,Y FISH testing more frequently to patients who 
declined diagnostic testing than to those at the initial appointment if there was an NIPT 
result positive for 45,X and ultrasound finding of cystic hygroma (scenario 2; p=0.015).  
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Table 4: Percent Of Prenatal Respondents Offering A Service By Scenario
Scenario Frequency
S1 Prenatal
CVS Amniocentesis CMA Single Gene Testing Anatomy U/S
Maternal 
Karyotype
Maternal 
X,Y FISH
Postnatal 
Evaluation
Other
Always 88.2 94.6 34.6 92.3 24.8 6.4 48.7 64.7
Often 7.1 4.6 17.8 6.2 19.1 8.5 18.3 11.8
Sometimes 0.0 0.8 22.4 1.6 26.7 12.8 17.4 0.0
Rarely 3.2 0.0 19.6 0.0 23.8 29.8 13.9 0.0
Never 1.6 0.0 5.6 0.0 5.7 42.6 1.7 23.5
Always 27.2 51.4 89.4 35.1 15.2 32.0 50.0
Often 12.0 12.5 5.7 21.3 15.2 14.7 0.0
Sometimes 20.7 12.5 2.4 24.5 21.2 21.3 14.3
Rarely 31.5 13.9 1.6 14.9 33.3 16.0 7.1
Never
8.7 9.7 0.8 4.3 15.2 16.0 28.6
Always 57.6 90.0 35.2 9.7 28.1 33.3
Often 12.1 3.3 23.1 12.9 8.8 0.0
Sometimes 13.6 4.2 23.1 29.0 24.6 11.1
Rarely 13.6 2.5 17.6 25.8 22.8 22.2
Never 3.0 0.0 1.1 22.6 15.8 33.3
Always
36.7 6.7 71.4 83.3
Often 15.6 10.0 17.0 8.3
Sometimes 24.4 30.0 6.3 0.0
Rarely 23.3 33.3 4.5 0.0
Never 0.0 20.0 0.9 8.3
S2 Prenatal
CVS Amniocentesis CMA Single Gene Testing Anatomy U/S
Maternal 
Karyotype
Maternal 
X,Y FISH
Postnatal 
Evaluation
Other
Always 94.3 95.`6 65.4 40.0 92.7 23.3 0.0 68.8 82.4
Often 4.1 4.0 14.0 15.2 4.0 6.7 0.0 13.5 11.8
Sometimes 0.8 0.8 11.2 21.0 3.2 15.0 15.4 12.5 0.0
Rarely 0.8 0.0 8.4 21.0 0.0 40.0 50.0 4.2 0.0
Never 0.0 0.0 0.9 2.9 0.0 15.0 34.6 1.0 5.9
Always
41.7 80.9 61.4 93.9 27.8 0.0 70.8 83.3
Often 15.5 10.9 16.7 4.4 11.1 3.6 12.4 5.6
Sometimes 17.9 5.5 14.9 1.7 22.2 25.0 14.6 5.6
Rarely 13.1 2.7 7.0 0.0 34.7 42.9 2.3 0.0
Never 11.9 0.0 0.0 0.0 4.2 28.6 0.0 5.6
Always 82.6 60.9 93.4 25.0 0.0 74.7 79.0
Often 10.1 18.3 3.3 17.7 7.4 11.0 0.0
Sometimes 5.5 16.5 3.3 17.7 29.6 13.2 5.3
Rarely 0.9 4.4 0.0 33.8 40.7 0.0 0.0
Never 0.9 0.0 0.0 5.9 22.2 1.1 15.8
Always 96.7 33.3 4.8 85.6 90.0
Often 1.6 11.1 4.8 7.6 0.0
Sometimes 1.6 30.6 38.1 5.1 0.0
Rarely 0.0 20.8 33.3 1.7 0.0
Never 0.0 4.2 10.1 0.0 10.0
S3 Prenatal
CVS Amniocentesis CMA Single Gene Testing Anatomy U/S
Maternal 
Karyotype
Maternal 
X,Y FISH
Postnatal 
Evaluation
Other
Always 96.6 60.7 45.6 8.7 75.3 66.7
Often 3.4 13.1 15.2 4.4 13.5 0.0
Sometimes 0.0 10.7 21.5 39.1 5.6 0.0
Rarely 0.0 9.5 12.7 21.7 4.5 0.0
Never 0.0 6.0 5.1 26.1 1.1 33.3
Always 66.7 52.4 8.7 51.5 50.0
Often 8.0 19.1 13.0 9.1 0.0
Sometimes 9.3 13.1 30.4 12.1 0.0
Rarely 9.3 14.3 30.4 12.1 0.0
Never 6.7 1.2 17.4 15.2 50.0
Always 51.3 6.7 85.1 50.0
Often 16.3 6.7 9.4 0.0
Sometimes 16.3 34.8 3.7 25.0
Rarely 12.5 26.1 1.9 0.0
Never 3.8 21.7 0.0 25.0
S4 Prenatal
CVS Amniocentesis CMA Single Gene Testing Anatomy U/S
Maternal 
Karyotype
Maternal 
X,Y FISH
Postnatal 
Evaluation
Other
Always 97.4 62.8 22.2 0.0 82.6 40.0
Often 1.7 11.5 8.3 10.5 9.3 0.0
Sometimes 0.0 16.7 13.9 36.8 5.8 0.0
Rarely 0.0 7.7 25.0 31.6 1.2 0.0
Never 0.9 1.3 30.6 21.1 1.2 60.0
Always 64.3 27.0 5.3 54.7 33.3
Often 10.0 2.7 0.0 14.1 0.0
Sometimes 7.1 24.3 26.3 10.9 0.0
Rarely 12.9 27.0 42.1 9.4 0.0
Never 5.7 18.9 26.3 10.9 66.7
Always 33.3 0.0 87.5 33.3
Often 11.1 10.5 5.8 0.0
Sometimes 8.3 21.1 1.9 0.0
Rarely 33.3 42.1 3.9 0.0
Never 13.9 26.3 1.0 66.7
Initial 
Appointment
Normal 46, XX 
CVS
Frequency Services Offered (% of Respondents)
No Diagnostic 
Testing
Initial 
Appointment
Normal 46, XX 
Amniocentesis
No Diagnostic 
Testing
Initial 
Appointment
Normal 46, XX 
CVS
Normal 46, XX 
Amniocentesis
Normal 46, XX 
Amniocentesis
No Diagnostic 
Testing
Initial 
Appointment
Normal 46, XY 
Amniocentesis
No Diagnostic 
Testing
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Pediatric section 
A total of 41 individuals were eligible to take the pediatric specific portion of the 
survey.  Of these respondents 82.5% indicated that they have seen at least one patient 
referred for a prenatal NIPT positive for a sex chromosome abnormality (Table 2).  The 
most common SCA seen by counselors in the last year was 45,X (72.7%) followed by 
47,XXY (63.6%), 47,XXX (45.5%), 47,XYY (24.2%), and “other” SCA results (6.1%), (Table 
2).  When asked about their comfort in counseling patients for the various SCA conditions, 
greater than 70% of respondents indicated that they were somewhat or extremely 
comfortable counseling patients about any of the potential SCAs (Figure 2; Table 5).  
Compared to 45,X, pediatric counselors were significantly less comfortable counseling 
patients about 47,XXX (p=0.033), 47,XYY (p=0.033), and “other” SCA results (p=0.016).  
No other significant differences were observed when comparing comfort between the other 
conditions.    
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Figure 2:  Pediatric Genetic Counselor Comfort Level 
About Discussing Various SCA Conditions With Patients
45, X 47, XXY 47, XXX 47, XYY Other
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When asked what they would offer at an initial appointment for a newborn with 
prenatal NIPT positive for 45,X, with or without physical features indicative of 45,X 
(scenarios 1 and 2), 47,XXX (scenario 3), or 47,XYY (scenario 4), the majority of pediatric 
genetic counselors (>70%) indicated they always offer a karyotype to patients (Table 6).  
The remaining options, including X,Y FISH, maternal karyotype, CMA, ultrasound, and 
echocardiogram were variable in the frequency with which they were offered within and 
between scenarios (Table 6).  More than 50% of respondents indicated they always offer 
X,Y FISH at the initial appointment, but that number decreased if the baby had a normal 
karyotype for all scenarios and was not statistically significant (p=0.333).  Compared to the 
initial appointment, respondents were significantly more likely to offer a maternal karyotype 
following normal diagnostic testing for newborns with NIPT positive for 45,X with physical 
findings indicative of 45,X (scenario 1; p=0.048), and newborns with NIPT positive for 
47,XXX (scenario 3; p=0.047).  When considering imaging options, echocardiogram was 
offered significantly more frequently for a newborn with prenatal NIPT positive for 45,X and 
webbed neck and puffy hands (scenario 1) at the initial appointment than following a 
normal karyotype (p=0.018).  Looking between scenarios, echocardiogram was offered 
significantly more frequently if a newborn with a prenatal NIPT positive for 45,X had 
physical findings indicative of 45,X (scenario 1) than if they did not have physical findings 
(scenario 2; p=0.026).  When asked about ultrasound (pelvic/renal/abdominal), 
respondents were significantly more likely to offer an ultrasound at the initial appointment 
Table 5: Pediatric Respondents Self-Reported Comfort Level Counseling About SCA Conditions
Pediatric Comfort 45, X 47, XXY 47, XXX 47, XYY Other
Extremely Uncomfortable 7.7% (n=2) 7.7% (n=2) 7.7% (n=2) 7.7% (n=2) 3.9% (n=1)
Somewhat Uncomfortable 3.9% (n=1) 3.9% (n=1) 7.7% (n=2) 7.7% (n=2) 7.7% (n=2)
Neither Comfortable nor 
Uncomfortable
7.7% (n=2) 15.4% (n=4) 7.7% (n=2) 11.5% (n=3) 11.5% (n=3)
Somewhat Comfortable 19.2% (n=5) 19.2% (n=5) 34.6% (n=9) 26.9% (n=7) 46.2% (n=12)
Extremely Comfortable 61.5% (n=16) 53.9% (n=14) 42.3% (n=11) 46.2% (n-12) 30.8% (n=8)
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for a baby with prenatal NIPT positive for 45,X who has a webbed neck and puffy hands 
(scenario 1) than they were if the baby had normal karyotype results (p= 0.027). 
 
 
 
 
 
 
Table 6: Percent of Pediatric Respondents Offering A Service By Scenario
S1 Pediatric 
X, Y FISH Karyotype CMA U/S (Pelvic/Renal/Abdominal)
Maternal 
Karyotype
Echocardiogram Other
Always 
52.2 84.9 32.0 50.0 5.9 70.0 50.0
Often 13.0 6.1 16.0 10.0 11.8 16.7 0.0
Sometimes 17.4 6.1 20.0 5.0 23.5 10.0 25.0
Rarely 17.4 0.0 28.0 35.0 52.9 3.3 0.0
Never 0.0 3.0 4.0 0.0 5.9 0.0 25.0
Always 16.7 28.6 37.5 28.6 52.4 33.3
Often 41.7 38.1 12.5 21.4 23.8 16.7
Sometimes 8.3 23.8 25.0 21.4 19.1 16.7
Rarely 16.7 9.5 12.5 21.4 4.8 16.7
Never 16.7 0.0 12.5 7.1 0.0 16.7
S2 Pediatric
X, Y FISH Karyotype CMA U/S (Pelvic/Renal/Abdominal)
Maternal 
Karyotype
Echocardiogram Other
Always 64.3 73.1 28.6 36.4 28.6 52.9 100.0
Often 0.0 11.5 14.3 9.1 28.6 17.7 0.0
Sometimes 7.1 7.7 14.3 18.2 14.3 11.8 0.0
Rarely 14.3 7.7 42.9 27.3 28.6 17.7 0.0
Never 14.3 0.0 0.0 9.1 0.0 0.0 0.0
S3 Pediatric
X, Y FISH Karyotype CMA U/S (Pelvic/Renal/Abdominal)
Maternal 
Karyotype
Echocardiogram Other
Always 77.8 85.2 41.7 30.0 0.0
Often 0.0 3.7 33.3 20.0 0.0
Sometimes 11.1 7.4 0.0 30.0 100.0
Rarely 0.0 3.7 25.0 20.0 0.0
Never
11.1 0.0 0.0 0.0 0.0
Always 14.3 27.3 46.2 No responses 
Often 14.3 18.2 30.8 No responses 
Sometimes 0.0 9.1 15.4 No responses 
Rarely 57.1 36.4 7.7 No responses 
Never 14.3 9.1 0.0 No responses 
S4 Pediatric
X, Y FISH Karyotype CMA U/S (Pelvic/Renal/Abdominal)
Maternal 
Karyotype
Echocardiogram Other
Always 63.6 84.6 50.0 33.3 No responses
Often 18.2 3.8 25.0 0.0 No responses
Sometimes 0.0 0.0 8.3 33.3 No responses
Rarely 18.2 11.5 16.7 33.3 No responses
Never 0.0 0.0 0.0 0.0 No responses
Always 60.0 30.8 33.3 No responses
Often 20.0 30.8 16.7 No responses
Sometimes 0.0 7.7 50.0 No responses
Rarely 20.0 15.4 0.0 No responses
Never 0.0 15.4 0.0 No responses
Initial 
Appointment
Normal 46, XY 
Karyotype
Initial 
Appointment
Normal 46, XX 
Karyotype
Initial 
Appointment
Initial 
Appointment
Normal 46, XX 
Karyotype
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DISCUSSION 
The purpose of this study was to describe current prenatal and pediatric genetic 
counseling practice following NIPT results positive for a sex chromosome abnormality.  
One hundred and seventy-six clinical prenatal and pediatric genetic counselors completed 
a scenario-based survey about their current practice following positive NIPT for SCA.   
Comfort Level      
On both the prenatal and pediatric side, the majority of counselors (94% of prenatal 
and 80% of pediatric) indicated they have seen at least one case of NIPT positive for an 
SCA in the past year with respondents reporting seeing an average of 1.4-3.2 cases per 
year.  Monosomy X (45,X) was the most commonly seen indication with an average of 3.2 
cases for prenatal counselors and 2.5 cases for pediatric counselors.  
While the average number of SCA cases respondents are seeing in a year is 
relatively low, the majority of counselors self-report being somewhat or extremely 
comfortable counseling patients about the various SCA conditions.  Among prenatal 
counselors, greater than 80% indicated being somewhat or extremely comfortable 
counseling patients about any of the SCA conditions.  Among pediatric counselors, greater 
than 70% indicated being somewhat or extremely comfortable counseling patients about 
SCA conditions.  For counselors in both specialties, comfort decreased as the condition 
became less common (45,X= 47,XXY> 47,XXX> 47,XYY> other), (Tables 3 and 5).  While 
this can be attributed to the lower frequency of the more rare sex chromosome conditions, 
it may also reflect that there is a lack of attention given to less common SCAs during 
training.  The textbook, Genetics In Medicine, is used by many genetics training programs.  
While all four common sex chromosome abnormalities are mentioned, only Klinefelter 
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syndrome and Turner syndrome are discussed in detail (23).  The American College of 
Medical Genetics has a Genetics and Genomics Review Course that includes a list of 100 
syndromes every geneticist should know.  Turner syndrome and Klinefelter syndrome are 
the only sex chromosome abnormalities on the list (24).  With the rapid uptake of NIPT 
testing, the likelihood of seeing families with other SCA conditions has increased, thus 
training programs may need to incorporate additional lectures about sex chromosome 
abnormalities beyond Turner syndrome and Klinefelter syndrome.   
The vast majority of prenatal counselors indicated they are comfortable counseling 
patients for NIPT positive for SCAs; however, counselors who had been in the field for less 
than 5 years were significantly less comfortable counseling about all SCA conditions 
except 45,X (p<0.02).  This result was not found among pediatric counselors.  This finding 
could be indicative of several things.  First, there is the potential that prenatal counselors in 
the field for ≥5 years have seen an overall greater number of SCA cases through patients 
undergoing CVS and amniocentesis procedures.  This may have provided the foundational 
knowledge about these conditions prior to the introduction of NIPT.  Second, this may 
simply be a reflection of a new graduate’s overall lack of comfort or confidence, and as 
time goes on they will become more comfortable with the indications (25).   
Regardless of counselor comfort with SCA conditions, NIPT with analysis for SCAs 
has become routine.  Based on this survey, 30% of respondents always offered patients 
NIPT with SCA analysis and 64% indicated they offer NIPT with SCA analysis to patients at 
least some of the time.  Therefore, it is likely that the frequency with which counselors will 
see patients for this indication will only increase, making increased education about SCAs 
necessary. 
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Prenatal Practice      
In prenatal practice there was a general consensus that regardless of the indication, 
it is appropriate to offer diagnostic testing and an anatomy ultrasound to all patients.  
Offering these options is in line with ACMG and ACOG’s suggested testing strategy for 
NIPT (26, 27).  In contrast, there was little consensus about how often or in what situations 
CMA, single gene testing, maternal testing (karyotype or X,Y FISH), echocardiogram, and 
postnatal evaluation should be offered.  This variability is understandable given the lack of 
current professional society guidelines for SCA on NIPT, making it harder to determine 
when to consistently offer these services.   
While there was wide variability in frequency, respondents were significantly more 
likely to offer CMA testing to a patient with ultrasound abnormalities and a normal 
karyotype (p<0.01).  A 2012 study by Wapner et al. found that in pregnancies with a normal 
karyotype result, 1.7% had a relevant deletion or duplication on CMA and 6% had a 
relevant deletion or duplication on CMA if there was also an ultrasound abnormality (28).  
Based on this information, offering CMA even when there has been a normal karyotype 
may be appropriate.  Per the written survey responses, some of the nuance in frequency 
may come from the fact that some respondents only discuss CMA if the patient elects 
diagnostic testing, “I always discuss CMA if a patient elects a diagnostic test but I do not 
discuss it if the patient declined diagnostic testing.”  Respondents may offer either 
karyotype or CMA but not both, “at our clinic patients typically need to pick a karyotype or 
CMA.”   
The offer of maternal testing to uncover an undiagnosed maternal SCA in the 
prenatal scenarios was also highly variable.  For a patient with NIPT positive for 45,X with 
or without ultrasound abnormalities or a patient with NIPT positive for 47,XXX, maternal 
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testing was offered significantly more frequently if the fetus had a normal karyotype result 
(p<0.03) or the patient had declined diagnostic testing (p<0.02) than at the initial 
appointment.  Some respondents indicated they would offer maternal testing only after a 
fetus’ normal workup, if the mother appeared to have features concerning for Turner 
Syndrome, or if the testing laboratory indicated that the result might be maternal in origin 
instead of fetal.  Depending on the laboratory’s testing methodology, results may be 
reported as most likely maternal in origin, which is a more recent nuance of NIPT testing.  
While this may be a helpful way to guide what testing should be offered, this information is 
not available through every NIPT method.  Wang et al. previously reported that of the 
pregnancies in their sample with NIPT positive for an SCA, 8.6% were due to maternal 
abnormalities in X chromosome number (14).  This number seems sufficiently high to 
warrant a discussion of routinely offering maternal testing when a patient is seen with NIPT 
positive for SCA that could be caused by a maternal difference in X chromosome number.  
Maternal testing is also important because an undiagnosed maternal SCA can have 
important health implications.  Women with 45,X have increased lifelong risks for hearing 
loss, aortic root dilation, and fractures, and women with 47,XXX may be at risk of primary 
ovarian insufficiency (20, 21).  In addition, women with 45,X have an increased risk for a 
pregnancy with a SCA (22).  Diagnosing these individuals allows for appropriate future 
screening and management of several serious health problems.       
Postnatal evaluation was not offered by prenatal counselors as frequently as had 
been anticipated given that the PPV for positive NIPT for SCAs generally creates a 
concern of a true positive of 20-50%.  Counselors were most likely to offer this option to 
patients who declined diagnostic testing during the pregnancy.  Even in this situation, not 
all counselors indicated they would always refer patients for postnatal evaluation.  One free 
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response elucidated a potential reason for this, “we don't have a geneticist within 3 hours of 
our area.  The waiting list for genetics is also 9 months…We encourage patients to share 
their [NIPT] result with their pediatrician.”  Other respondents echoed the ideas that there 
either was not a geneticist within a reasonable distance of them and/or the waiting list to 
see medical genetics was anywhere from 6 months to upwards of 12 months.  It has been 
observed that fewer and fewer clinicians are seeking certification in clinical genetics, 
leading to fewer clinical geneticists today than 30 years ago (29).  A 2015 study stated that 
50% of available medical genetics residencies remain unfilled (30).  Therefore, while ideally 
all individuals with NIPT positive for SCA should have follow up at birth, referring these 
patients to a medical geneticist would put increased strain on an already limited resource.  
While several counselors indicated they encourage their patients to share abnormal NIPT 
results with their pediatrician following the birth of the baby, there is no guarantee that 
patients will inform their doctor of their positive NIPT results.  Therefore, healthcare teams 
should consider implementing a system where there is a direct physician to physician hand 
off of information, such as from obstetrics to pediatrics, to ensure all patients receive 
appropriate follow up.  Pediatricians then need to be involved in ordering a postnatal 
karyotype and making subsequent referrals to genetics as needed.   
Fetal echocardiogram was a common recommendation recorded as an “other” 
response for scenarios involving NIPT positive for 45,X with or without ultrasound findings 
(scenario 1 and 2).  Specifically, in a scenario where there was NIPT positive for 45,X and 
no ultrasound findings (scenario 1), several respondents indicated they would also offer an 
echocardiogram to a patient during the initial appointment or if diagnostic testing was 
declined.  In a scenario where there was NIPT positive for 45,X and a cystic hygroma on 
ultrasound (scenario 2), greater than 12 respondents indicated they would offer the patient 
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an echocardiogram regardless of whether it was at the initial appointment, after normal 
diagnostic studies, or with no diagnostic testing pursued.  Since fetal echocardiogram was 
not included in the original survey, it is not possible to draw conclusions about how 
frequently it is being offered to patients.  Future studies looking to find consensus on SCA 
practice may wish to include the potential of fetal echocardiogram in the discussion.  
Pediatric Practice 
In pediatric practice there was a general consensus that a karyotype should be 
offered to all newborns with a prenatal NIPT positive for an SCA that was unresolved 
regardless of whether the baby had any abnormal features.  This is in line with the ACMG 
and ACOG statement on NIPT which states postnatal karyotype should be offered to all 
patients who declined diagnostic testing in the prenatal setting (26, 27). However, there 
was little consensus about how often or in what situations X,Y FISH, maternal karyotype, 
CMA, ultrasound (renal/pelvic/abdominal), and echocardiogram should be offered.  
Pediatric respondents were more likely to offer a maternal karyotype if the neonate 
had a normal karyotype result but an unresolved NIPT positive for 45,X with physical 
findings indicative of 45,X (p=0.048) or an unresolved NIPT positive for 47,XXX (p=0.047).  
However, when there was a child with a positive NIPT result for 45,X with no findings and a 
normal karyotype, respondents were less likely to order a maternal karyotype.  These 
results seem contradictory since the lack of findings for a neonate with NIPT positive for 
45,X  should increase suspicion for maternal SCA. 
Like maternal testing, imaging studies were offered with high variability.  
Echocardiogram and abdominal ultrasound were offered more frequently at the initial 
appointment of a newborn with NIPT positive for 45,X  and physical findings indicative of 
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Turner syndrome than following normal karyotype (p<0.027), or if there were no physical 
findings at birth (p<0.027).  Since approximately 40% of individuals with Turner syndrome 
have heart defects and 60% have structural renal abnormalities, echocardiogram and 
imaging of the kidneys/abdomen is a common referral for a baby with potential Turner 
syndrome (31). 
Practice Implications 
Overall, this study suggests that many prenatal counselors are following current 
recommendations by offering diagnostic testing and ultrasound screening to patients with 
positive SCA results.  However, practice differs in offering specialty imaging, maternal 
karyotyping, and postnatal follow up.  Likewise, many pediatric counselors are 
recommending karyotyping babies with unresolved NIPT positive for SCA.  However, there 
is wide variability in this group regarding subsequent referral for specialty imaging and 
maternal karyotyping.  Therefore, while both prenatal and pediatric counselors self-
reported being comfortable with SCA conditions, they are not uniformly recommending 
appropriate follow up for their patients.  Early diagnosis with appropriate follow up and 
treatment is crucial for mitigating or preventing some of the medical problems associated 
with SCA conditions.  Children with 45,X can have cardiac abnormalities, renal 
abnormalities, ocular findings, and hearing loss and benefit from being followed by 
appropriate specialists.  Many also benefit from growth hormone treatment which can be 
started as early as the age of 2.  Individuals with 45,X who do not receive growth hormone 
early do not experience as great a benefit in the social and medical benefits associated 
with growth hormone treatment (20).  Individuals with 47,XXY may need lifelong 
testosterone supplementation to prevent symptoms and sequelae of androgen deficiency 
which include osteoporosis, muscle weakness, and increased risk for thromboembolic 
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events making early diagnosis of 47,XYY key (32).  In addition, there is evidence that early 
intervention improves social and developmental outcomes for children with SCAs making a 
strong case for the necessity of prompt follow up for all NIPT results positive for a SCA (20, 
33, 34).    
Both ACMG and ACOG concur that the limitations of NIPT must be discussed with 
patients, and that it is a reasonable screening option for aneuploidy.  While both mention 
that NIPT may also include analysis for SCA conditions, recommendations about the 
appropriate testing population and what follow up testing, other than a diagnostic 
procedure, should be offered following a positive result are not outlined for the SCA 
conditions (26, 27).  NSGC has likewise expressed its support for NIPT screening in the 
prenatal field but without any information about specific testing or screening that should be 
offered following a positive result (35).   
Because of the variability seen in what is being offered to patients and the benefits 
of early diagnosis and appropriate follow up for individuals with a SCA, there is a need for 
professional guidelines to help determine best practice and increase the cohesiveness of 
care that patients across the country are receiving.  While it is unlikely a single policy for 
follow up testing and screening would be applicable to every situation given the 
complexities that come with screening for SCA conditions, guidelines could provide a 
beneficial framework for genetic counseling.   
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Study Limitations 
 This study had several limitations.  First, there was a relatively poor response rate 
(8.6%) and thus overall small sample size compared to response rates from other surveys 
of prenatal and pediatric genetic counselors.  However, the study population appears to be 
representative of the national genetic counselor population based on demographic 
comparisons to the 2016 NSGC Professional Status Survey.  Second, the survey used for 
this study was not validated and questions could have been misinterpreted by those taking 
the survey.  Finally, the aim of this survey was to describe current counseling practice 
among prenatal and pediatric counselors for various SCA conditions reported on NIPT.  
Therefore, conclusions can only be made about current practice and do not reflect clinical 
practice before or after the survey was administered.  However, this study was the first of 
its kind and gives needed insight into the current practices of a representative sample of 
prenatal and pediatric genetic counselors who are seeing patients with NIPT results 
positive for SCAs and is therefore a useful addition to the current literature.  
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CONCLUSION 
Using NIPT to screen for sex chromosome abnormalities is common in prenatal 
practice.  With the increase in screening comes an increase in results positive for SCAs 
and subsequently more patients being referred for genetic counseling for an unresolved 
SCA result.  While counselors largely report being comfortable counseling patients for this 
indication and there is general consensus about recommending prenatal or postnatal 
karyotype, maternal testing, specialty screening, and postnatal evaluation practices are 
inconsistent. This study demonstrates a need for collaboration among clinicians and 
governing bodies to create specific practice guidelines from which genetic counselors and 
other clinicians may base their practice and bring uniformity to the care of patients for this 
type of indication.    
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APPENDIX 
Survey Questions 
Demographic Information 
1.  Which setting do you currently work in? 
a. University Medical Center    
b. Public Hospital/Medical Facility   
c. Private Hospital/Medical Facility    
d. Diagnostic Laboratory    
e. Physician's Private Practice    
f. Other: (Free response) 
2. Do you see prenatal or pediatric patients as part or all of your position? 
a. Yes    
b. No  
3. What is your current specialty? (Please select all that apply) 
a. Prenatal   
b. Pediatric   
c. Cancer   
d. General Genetics   
e. Adult    
f. Other: (Free response) 
4. How many years have you worked in the prenatal genetic counseling field? 
a. 1 ... 20+  
5. How many prenatal patients do you see per week? 
a. 1-10    
b. 11-20    
c. 21-30    
d. 31-40    
e. 41-50    
f. 51+    
6. How many years have you worked in the pediatric genetic counseling field? 
a. 1 ... 20+  
7. How many pediatric patients do you see per week? 
a. 1-10    
b. 11-20    
c. 21-30    
d. 31-40    
e. 41-50    
f. 51+    
8. How many years have you worked in the genetic counseling field overall? 
a. 1 ... 20+ 
9 What state do you currently work in?  
a. Alabama  
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b. Alaska   
c. Arizona  
d. Arkansas  
e. California  
f. Colorado  
g. Connecticut  
h. Delaware  
i. Florida   
j. Georgia    
k. Hawaii    
l. Idaho    
m. Illinois    
n. Indiana    
o. Iowa    
p. Kansas    
q. Kentucky    
r. Louisiana    
s. Maine    
t. Maryland    
u. Massachusetts  
v. Michigan    
w. Minnesota    
x. Mississippi    
y. Missouri    
z. Montana    
aa. Nebraska    
bb. Nevada   
cc. New Hampshire   
dd. New Jersey    
ee. New Mexico  
ff. New York  
gg. North Carolina    
hh. North Dakota    
ii. Ohio    
jj. Oklahoma    
kk. Oregon   
ll. Pennsylvania    
mm. Rhode Island   
nn. South Carolina    
oo. South Dakota    
pp. Tennessee    
qq. Texas    
rr. Utah    
ss. Vermont    
tt. Virginia   
uu. Washington   
vv. West Virginia    
ww. Wisconsin    
xx. Wyoming    
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Pediatric Arm 
10.  Have you seen at least one patient who was referred postnatally due to a 
positive/increased risk cell free DNA (cfDNA, NIPT) result for a sex chromosome 
abnormality during pregnancy?  
a. Yes    
b. No   
11.  Please estimate how many patients you have seen in the past year who were referred 
for a positive cell free DNA result during pregnancy for the below conditions. 
a. 45,X ________________________________________________ 
b. 47,XXX ________________________________________________ 
c. 47,XXY ________________________________________________ 
d. 47,XYY ________________________________________________ 
e. Other: ________________________________________________ 
12.  Scenario 1: 
You are seeing a newborn with a prenatal cell free DNA result positive for Turner 
Syndrome who had a normal anatomy ultrasound and no diagnostic testing.  At birth, 
physical findings include a webbed neck and puffy hands. 
13.  What percentage of the time do you offer or refer the family for the following options at 
the initial appointment?   
a. X,Y FISH    
b. Karyotype    
c. CMA 
d. Pelvic/Renal/Abdominal Ultrasound  
e. Maternal Blood Karyotype    
f. Echocardiogram    
g. Other: (free response)    
14.  If the family opts for chromosome testing and the results are normal 46, XX, what 
percentage of the time do you offer or refer for the following options? 
a. X,Y FISH    
b. CMA   
c. Pelvic/Renal/Abdominal Ultrasound   
d. Maternal Blood Karyotype   
e. Echocardiogram    
f. Other    
15.  If the baby had physical findings including a webbed neck and puffy hands but normal 
46, XX diagnostic testing during pregnancy, would your recommendations change? 
a. Yes  
b. No   
16.  If yes, what percentage of the time would you offer or refer for the following options? 
a. X,Y FISH    
b. Karyotype   
c. CMA   
d. Pelvic/Renal/Abdominal Ultrasound   
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e. Maternal Blood Karyotype    
f. Echocardiogram    
g. Other   
17.  If you would like to provide more information on your counseling/testing strategy for 
this scenario please do so below.  (Free response) 
18.  Scenario 2:  
You are seeing a newborn with a prenatal cell free DNA result positive for Turner 
Syndrome who had a normal female anatomy ultrasound and no diagnostic testing.  At 
birth, no physical signs of Turner Syndrome are appreciated.   
19.  What percentage of the time would you offer or refer for the following options at the 
initial appointment? 
a. X,Y FISH    
b. Karyotype   
c. CMA   
d. Pelvic/Renal/Abdominal Ultrasound    
e. Maternal Blood Karyotype   
f. Echocardiogram    
g. Other   
20.  If you would like to provide more information on your counseling/testing strategy for 
this scenario please do so below. (Free response) 
 
21. Scenario 3: 
You are seeing a newborn with a prenatal cell free DNA result positive for 47,XXX who had 
a normal anatomy ultrasound and no diagnostic testing.  At birth there are no physical 
findings.  
22.  What percentage of the time would you offer the following options at the initial 
appointment? 
a. X,Y FISH    
b. Karyotype    
c. CMA   
d. Maternal Blood Karyotype    
e. Other 
23.  If the family opts for chromosomes and the results are normal 46, XX, what percentage 
of the time would you offer the following options? 
a. X,Y FISH   
b. CMA   
c. Maternal Blood Karyotype   
d. Other   
24.  If you would like to provide more information on your counseling/testing strategy for 
this scenario please do so below.  (Free response) 
25.  Scenario 4: 
You are seeing a newborn with a prenatal cell free DNA result positive for 47,XYY who had 
a normal anatomy ultrasound and no diagnostic testing.  At birth there are no abnormal 
physical findings. 
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26.  What percentage of the time do you offer the following options to patients at the initial 
appointment? 
a. X,Y FISH    
b. Karyotype    
c. CMA    
d. Maternal Blood Karyotype    
e. Other   
27.  If the family opts for chromosome testing and the results are normal 46, XY, what 
percentage of the time would you offer the following options? 
a. X,Y FISH   
b. CMA  
c. Maternal Blood Karyotype    
d. Other   
28.  If you would like to provide more information on your counseling/testing strategy for 
this scenario please do so below.  (Free response) 
 
29.  How comfortable do you feel discussing a positive cell free DNA result for a sex 
chromosome abnormality with a pediatric patient? 
 Extremely 
Uncomfortable 
Somewhat 
Uncomfortable 
Neither 
Comfortable nor 
Uncomfortable 
Somewhat 
Comfortable 
Extremely 
Comfortable 
45,X      
47,XXX      
47,XXY      
47,XYY      
Other: 
SCA 
     
 
30.  Which of the following do you take into consideration when deciding what to discuss 
and offer when counseling a pediatric patient about a positive cell free DNA result for the 
below sex chromosome abnormalities? Select all that apply.  
 45,X 47,XXX 47,XXY 47,XYY 
Lack of Physical Findings     
Risk of Mosaicism     
Potential to Uncover a Maternal 
SCA 
    
Potential to Uncover a Paternal 
SCA 
    
Other:     
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Prenatal Arm 
31.  Does your office offer cell free DNA testing (cfDNA, NIPT)? 
a. Yes    
b. No   
32.  When offering cell free DNA testing (cfDNA, NIPT) what percent of the time do you 
offer each of the following options? 
a. NIPT (18, 21, Y)   
b. NIPT (13, 18, 21, Y)   
c. NIPT (13, 18, 21) with Sex Chromosome Aneuploidy   
d. NIPT with Sex Chromosome Aneuploidy and Microdeletions   
33.  Does your office offer diagnostic testing to patients? 
 No Yes 
CVS   
Amniocentesis   
 
 
34.  Does your office see patients who are referred in for a positive cell free DNA result for 
sex chromosome abnormalities? 
a. Yes    
b. No   
35.  When discussing a positive cell free DNA result for sex chromosome abnormalities 
how often do you discuss positive predictive value PPV with the patient? (percent of 
time)   
36.  If you discuss PPV, how do you determine the PPV used in your counseling? Select all 
that apply 
a. I calculate my own using the Gil et al, 2015 Meta-Analysis paper (by hand or 
using an online calculator)  
b. I calculate my own using lab specific sensitivity and specificity   
c. I use the PPV the laboratory reports on the test results   
d. I use PPV published in primary literature   
e. Other: (Free response) 
37.   Have you seen at least one patient with a cell free DNA result positive for a sex 
chromosome abnormality? 
a. Yes    
b. No  
38.  Please list how many patients you have seen in the past year with a positive/increased 
risk cell free DNA result for the below conditions? 
a. 45,X ________________________________________________ 
b. 47,XXX ________________________________________________ 
c. 47,XXY ________________________________________________ 
d. 47,XYY ________________________________________________ 
e. Other:  ________________________________________________ 
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39. Scenario 1: 
You are seeing a 35-year-old woman at 12 weeks who has a cell free DNA result positive 
for Turner Syndrome and no ultrasound findings. 
(For the following questions, consider what you discuss or offer even if it would be 
performed at a later date) 
40.  What percentage of the time do you discuss the following options at the initial 
appointment?  
a. CVS    
b. Amniocentesis    
c. Anatomy Ultrasound    
d. CMA   
e. Maternal Karyotype    
f. Maternal X,Y FISH    
g. Postnatal Evaluation by a Geneticist    
h. Other   
41.  If the patient opts for a CVS and the results are normal 46, XX, what percentage of the 
time would you offer the following for follow-up testing? 
a. Amniocentesis   
b. Anatomy Ultrasound   
c. CMA  
d. Maternal Karyotype    
e. Maternal X,Y FISH  
f. Postnatal Evaluation by a Geneticist    
g. Other   
42.  If the patient declines CVS and opts for amniocentesis at 16 weeks and the results are 
normal 46, XX, what percentage of the time would you offer the following for follow-up 
testing? 
a. Anatomy Ultrasound    
b. CMA  
c. Maternal Karyotype    
d. Maternal X,Y FISH  
e. Postnatal Evaluation by a Geneticist    
f. Other   
43.  If the patient declines diagnostic testing, has a normal 20 week anatomy scan with no 
ultrasound findings, and is continuing the pregnancy, what percentage of the time would 
you offer the following for follow-up testing? 
a. Maternal Karyotype    
b. Maternal X,Y FISH    
c. Postnatal Evaluation by a Geneticist   
d. Other   
44.  If you would like to provide more information on your counseling/testing strategy for 
this scenario please do so below.  (Free response) 
45. Scenario 2: 
You are seeing a 35-year-old woman at 12 weeks with a cell free DNA result positive for 
Turner Syndrome and a cystic hygroma on ultrasound. 
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(For the following questions, consider what you discuss or offer even if it would be 
performed at a later date) 
46.  What percentage of the time do you discuss the following options at the initial 
appointment?  
a. CVS    
b. Amniocentesis    
c. Anatomy Ultrasound    
d. CMA  
e. Single Gene Testing Such as Noonan Syndrome    
f. Maternal Chromosomes  
g. Maternal X,Y FISH   
h. Postnatal Evaluation by a Geneticist    
i. Other:  
47.  If the patient opts for a CVS and the results are normal 46, XX, what percentage of the 
time do you offer the following for follow-up testing? 
a. Amniocentesis   
b. Anatomy Ultrasound    
c. CMA  
d. Single Gene Testing Such as Noonan Syndrome   
e. Maternal Chromosomes    
f. Maternal X,Y FISH  
g. Postnatal Evaluation by a Geneticist    
h. Other  
48.  If the patient declines CVS and opts for amniocentesis at 16 weeks and the results are 
normal 46, XX, what percentage of the time do you offer the following for follow-up testing? 
a. Anatomy Ultrasound  
b. CMA  
c. Single Gene Testing Such as Noonan Syndrome    
d. Maternal Chromosomes    
e. Maternal X,Y FISH   
f. Postnatal Evaluation by a Geneticist    
g. Other   
49.  If the patient declines diagnostic testing and is continuing the pregnancy, what 
percentage of the time would you offer the following for follow-up testing? 
a. Anatomy Ultrasound    
b. Maternal Chromosomes    
c. Maternal X,Y FISH    
d. Postnatal Evaluation by a Geneticist    
e. Other   
50.  If you would like to provide more information on your counseling/testing strategy for 
this scenario please do so below.  (Free response) 
51. Scenario 3: 
You are seeing a 35-year-old woman at 20 weeks with a cell free DNA result positive for 
47,XXX and a normal anatomy scan. 
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(For the following questions, consider what you discuss or offer even if it would be 
performed at a later date) 
 
52.  What percentage of the time do you discuss the following options at the initial 
appointment?  
a. Amniocentesis   
b. CMA  
c. Maternal Karyotype    
d. Maternal X,Y FISH  
e. Postnatal Evaluation by a Geneticist    
f. Other   
53.  If the patient opts for amniocentesis and the results are normal 46, XX, what 
percentage of the time would you offer the following for follow-up testing? 
a. CMA    
b. Maternal Blood Karyotype    
c. Maternal X,Y FISH    
d. Postnatal Evaluation by a Geneticist   
e. Other   
54.  If the patient declines diagnostic testing and is continuing the pregnancy, what 
percentage of the time would you offer the following for follow-up testing? 
a. Maternal Karyotype   
b. Maternal X,Y FISH  
c. Postnatal Evaluation by a Geneticist    
d. Other   
55.  If you would like to provide more information on your counseling/testing strategy for 
this scenario please do so below.  (Free response) 
56.  If the above patient is instead 25 years old would your recommendations change? 
a. Yes    
b. No   
57 If yes, how would they change?  (Free response) 
58. Scenario 4: 
You are seeing a 35-year-old woman at 20 weeks with a cell free DNA result positive for 
47,XYY and a normal anatomy scan. 
(For the following questions, consider what you discuss or offer even if it would be 
performed at a later date) 
59.  What percentage of the time do you discuss the following options at the initial 
appointment?  
a. Amniocentesis  
b. CMA   
c. Maternal Blood Karyotype   
d. Maternal X,Y FISH  
e. Postnatal Evaluation by a Geneticist    
f. Other   
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60.  If the patient opts for amniocentesis and the results are normal 46 XY, what 
percentage of the time would you offer the following for follow-up testing? 
a. CMA   
b. Maternal Blood Karyotype    
c. Maternal X,Y FISH    
d. Postnatal Evaluation by a Geneticist   
e. Other   
61.  If the patient declines diagnostic testing and is continuing the pregnancy, what 
percentage of the time would you offer the following for follow-up testing? 
a. Maternal Blood Karyotype    
b. Maternal X,Y FISH    
c. Postnatal Evaluation    
d. Other   
62.  If you would like to provide more information on your counseling/testing strategy for 
this scenario please do so below.  (Free response) 
63.  How comfortable do you feel discussing a positive cell free DNA result for a sex 
chromosome abnormality with a prenatal patient? 
 Extremely 
Uncomfortable 
Somewhat 
Uncomfortable 
Neither 
Comfortable nor 
Uncomfortable 
Somewhat 
Comfortable 
Extremely 
Comfortable 
45,X      
47,XXX      
47,XXY      
47,XYY      
Other: 
SCA 
     
 
64.  Which of the following do you take into consideration when deciding what to discuss 
and offer when counseling a prenatal patient about a positive cell free DNA result for the 
below sex chromosome abnormalities? Select all that apply.  
 45,X 47,XXX 47,XXY 47,XYY 
Lack of Physical Findings     
Risk of Mosaicism     
Potential to Uncover a Maternal SCA     
Potential to Uncover a Paternal SCA     
Other     
I Offer the Same Options to All My Patients with a 
cfDNA Result Positive for a SCA 
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